Class Action Lawsuit for Investors in Sage Therapeutics
The Law Offices of Frank R. Cruz has made a noteworthy move in support of investors in Sage Therapeutics, Inc. (NASDAQ: SAGE). A class action lawsuit has been filed for individuals and entities that acquired securities related to this well-known biotechnology firm. This legal action specifically targets those who bought these securities during the designated Class Period.
What You Need to Know About the Class Period
The Class Period for this lawsuit spans from April 12, 2021, to July 23, 2024. Investors should take careful note of this timeframe, as it marks when the alleged misleading statements about the company’s performance and future were issued. Shareholders who experienced losses during this period are encouraged to act promptly by submitting a lead plaintiff motion before the deadline approaches.
Recent Events Impacting Sage Therapeutics
Recently, significant developments have shaken Sage's stock performance and raised alarms among investors. For example, on August 4, 2023, Sage announced it had received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application for zuranolone, but only for treating postpartum depression (PPD). The application for major depressive disorder (MDD) received a Complete Response Letter, signaling that the FDA needed more compelling evidence to approve it. This revelation led to a drastic drop in Sage's stock, which fell by 53.6% and closed at $16.75 per share on August 7, 2023.
Additional Disclosures Affecting Stock Prices
On April 17, 2024, Sage disclosed that its Phase 2 study for SAGE-718, aimed at treating mild cognitive impairment due to Parkinson’s Disease, did not achieve its primary endpoint. The disappointing results prompted the company to halt further development of SAGE-718 in this area, resulting in another 19.6% decline in its stock price.
Even further unfortunate news followed; on July 24, 2024, Sage reported that a Phase 2 trial involving Sage-324 for essential tremor yielded unsatisfactory results, showing no significant differences compared to the placebo. This announcement caused yet another decrease in stock price, dropping by 20.6% and closing at $10.38 per share, compounding the financial impact on shareholders.
Claims in the Class Action Lawsuit
The class action complaint claims that throughout the Class Period, key executives allegedly misled shareholders through materially false statements regarding the effectiveness and marketability of the company's products. These claims indicate that the misinformation about zuranolone, SAGE-718, and SAGE-324 inflated the company's stock price in a deceptive way.
In particular, the lawsuits suggest that executives implied zuranolone would likely obtain FDA approval for MDD, which they later claimed it would not. Such misrepresentation has severely distorted the clinical and commercial outlook of other crucial products, prompting investors to respond.
How Investors Can Join the Class Action
If you're a shareholder who bought Sage Therapeutics shares during the Class Period, it’s vital to act without delay. The deadline for moving the Court to appoint you as lead plaintiff is October 28, 2024. Although potential class members aren't required to act immediately, they can choose to seek legal representation or opt out of the proceedings.
Contact Details for Interested Investors
If you have questions about the class action or want more information on potential claims, Frank R. Cruz and his skilled team at The Law Offices of Frank R. Cruz are ready to help. Investors can reach the office at 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 or by phone at 310-914-5007. You can also send queries via email; just make sure to include your name, mailing address, phone number, and details about the shares you purchased.
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The class action lawsuit aims to represent investors who bought Sage Therapeutics securities during the Class Period and experienced financial losses.
Who can participate in this lawsuit?
Any individual or entity that purchased Sage Therapeutics shares within the specified time frame can potentially join the class action.
What are the allegations against Sage Therapeutics?
The lawsuit claims that the company made materially false statements about its products, misleading investors about their effectiveness and the chances of regulatory approval.
When is the deadline to file a lead plaintiff motion?
The deadline to file a lead plaintiff motion is October 28, 2024.
How can investors get more information regarding the lawsuit?
Investors can contact The Law Offices of Frank R. Cruz for details about the lawsuit or consult their legal counsel for more guidance.
